Special Issue

Pharmacologic Therapy for Traumatic Brain Injury

Message from the Guest Editor

Traumatic brain injury (TBI) is an insult to the brain from an external force that causes temporary or permanent impairment in functional, psychosocial, or physical abilities, TBI-the "silent epidemic"-contributes to worldwide death and disability more than any other traumatic insult. According to the World Health Organization, TBI became the third leading cause of mortality amongst all age groups in the year 2020. While there is much promising work under way, there are significant opportunities to focus on areas such as mild TBI, the post-acute and chronic TBI periods, and on therapies targeting mechanisms of neurorepair and neuroregeneration. Thus, the challenges that combination therapy presents are only beginning to be addressed, and it is likely that polypharmacy will eventually be needed to achieve maximal recovery after TBI. In this Special Issue, we focus on how new pharmacological approaches can prevent negative clinical symptoms and neurodegeneration for particular TBI clinical scenarios.

Guest Editor

Prof. Dr. Liubov Gorbacheva

Department of Human and Animal Physiology, Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia

Deadline for manuscript submissions

closed (31 May 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/105343

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

